Revenue Comparison
Chart: Revenue Comparison. Values in USD billions. In Q2 2026: Merck & Co. 16.607, Moderna 0.145.
Merck & Co. vs Moderna Net Worth and Market Cap
Merck & Co. (MRK) and Moderna (MRNA) are peers in Vaccines. Merck & Co. reported revenue of $16.6B as of Q2 2026, compared with $145M for Moderna. Merck & Co. leads on revenue.
Merck & Co.'s gross margin is 73.5% versus 35.9% for Moderna. Merck & Co.'s net margin is -8.0% versus -539.3% for Moderna.
Key differences
- Revenue growth from Q2 2025 to Q2 2026: Merck & Co. +5.1%, Moderna +2.1%.
- Both made operating losses in their latest quarter: Merck & Co. at a -4.1% margin, Moderna at -562.1%.
- Merck & Co.'s KPIs on Sterling include Merck Animal Health Livestock vs Companion Animal (Quarterly) and Merck Gardasil China Sales as Printed.
- Moderna's KPIs on Sterling include Cash, Cash Equivalents and Investments (Quarterly) and Net Product Sales vs Deferred Revenue (Quarterly).
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Merck & Co., Moderna.| Metric | Merck & Co. | Moderna |
|---|---|---|
| Market Cap | - | - |
| Revenue | $16.61B | $145.00M |
| Cost of Revenue | $4.39B | $93.00M |
| Gross Profit | $12.21B | $52.00M |
| Operating Income | $-683.00M | $-815.00M |
| Net Income | $-1.33B | $-782.00M |
| R&D Expense | $9.74B | $651.00M |
| Earnings Per Share | -$0.54 | -$1.96 |
| Gross Margin | 73.5% | 35.9% |
| Operating Margin | -4.1% | -562.1% |
| Net Profit Margin | -8.0% | -539.3% |
| Free Cash Flow | $4.48B | $-563.00M |
| Cumulative Free Cash Flow | $249.70B | $7.37B |
| Operating Cash Flow | $5.37B | $-526.00M |
| Cash & Equivalents | $6.85B | $1.72B |